@talkoutput78
Active 9 months ago
reening in the UK.
Teprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of active Thyroid eye disease (TED). The current study reviews its efficacy in chronic TED.
In this retrospective review, consecutive patients with chronic stable TED (>2 years), who had received ≥3 infusions of t […] View
Sorry, there was no activity found. Please try a different filter.